Skip to main contentAll experts

DrNicole Iovine

INTERIM CHAIR & CLIN PROF

MD-MEDICINE

Orcid identifier0000-0002-5032-6485 (opens in a new tab)⁠
  • INTERIM CHAIR & CLIN PROF
    MD-MEDICINE

GRANTS

  • GRANT
    Phase 2 clinical trial platform investigating multiple therapeutic options for the treatment of hospitalized patients with acute respiratory distress syndrome (ARDS)
    Biomedical Advanced Research & Devlpmt Author1 Jul 2026 - 30 Jun 2031
    Active
  • GRANT
    A SINGLE-ARM, OPEN-LABEL, PROSPECTIVE, OBSERVATIONAL STUDY TO ASSESS THE SAFETY OF SULBACTAM-DURLOBACTAM, INCLUDING THE RISK OF HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS) IN PARTICIPANTS WITH ACINETOBACTER BAUMANNII-CALCOACETICUS COMPLEX INFECTION
    Entasis Therapeutics17 Feb 2026 - 16 Feb 2031
    Active
  • GRANT
    Researching COVID to Enhance Recovery - Treating Long COVID (RECOVER-TLC)
    National Institute of Health Nhlbi16 Oct 2025 - 31 Dec 2028
    Active
  • GRANT
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Nonhospitalized Participants
    Gilead Sciences10 Jan 2025 - 13 Jan 2025
    Closed
  • GRANT
    Utilizing phylodynamic and causal artificial intelligence methods for predicting and characterizing antibiotic resistant bacterial transmission within and beyond hospital settings
    National Institute of Health Niaid22 Nov 2024 - 31 Dec 2027
    Active
  • GRANT
    A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAL02 ADMINISTERED INTRAVENOUSLY IN ADDITION TO STANDARD OF CARE IN SUBJECTS WITH SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
    Eagle Pharmaceuticals8 Jan 2024 - 7 Jan 2029
    Active
  • GRANT
    A Phase 2/3 Single-Arm, Open-label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Obeldesivir in Pediatric Participants With COVID-19
    Gilead Sciences27 Nov 2023 - 13 Dec 2024
    Closed
  • GRANT
    A Multicenter, Adaptive, Randomized, Blinded Controlled Trial Platform To Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections
    National Institute of Health Niaid10 Aug 2023 - 30 May 2025
    Expired
  • GRANT
    A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease
    National Institute of Health Niaid18 Nov 2022 - 30 Nov 2025
    Expired
  • GRANT
    A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
    National Institute of Health Nci8 Sep 2021 - 31 Oct 2022
    Expired
  • GRANT
    ACTIV 4d RAAS
    National Institute of Health Nhlbi28 Jul 2021 - 31 Mar 2024
    Expired
  • GRANT
    Prevalence of Cefazolin Inoculum Effect in Mcthicillin Susceptible Staphylococcus aureus Bacteremia
    UF Health Shands Hospital16 Apr 2021 - 1 Jul 2024
    Expired
  • GRANT
    COVID-19: A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitals Adults with COVID-19
    National Institute of Health Nhlbi13 Oct 2020 - 30 Jun 2024
    Expired
  • GRANT
    A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
    National Institute of Health Niaid26 Mar 2020 - 30 Aug 2021
    Expired
  • GRANT
    Mucusal and Systemic Immunity, Vaccines and Microbiota Interplay in Humans
    National Institute of Health Niaid1 Sep 2016 - 31 May 2018
    Expired
  • GRANT
    Campylobacter jejuni and Reactive Nitrogen Species (opens in a new tab)⁠
    National Institute of Allergy and Infectious Diseases1 Jul 2005 - 31 May 2009
    People funded by this grant:
    • IOVINE NM
    MORELEARN MORE (opens in a new tab)